subject: Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis And Market Forecasts To 2016 [print this page] Idiopathic Pulmonary Fibrosis - Drug Pipeline Analysis and Market Forecasts to 2016
Summary
Report on the pharmaceutical and healthcare industry - Idiopathic Pulmonary Fibrosis Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global idiopathic pulmonary fibrosis market. This pharma report identifies the key trends shaping and driving the global idiopathic pulmonary fibrosis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global idiopathic pulmonary fibrosis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis team of industry experts.
Scope
The scope of the report includes:
- Annualized global idiopathic pulmonary fibrosis revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
- Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
- Analysis of the current and future market competition in the global idiopathic pulmonary fibrosis market. Key players covered include Gilead Sciences, Inc, Actelion Ltd., Amgen Inc, InterMune, Inc. and Amarillo Biosciences
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the future market associated with idiopathic pulmonary fibrosis.
